Cell-free DNA: measurement in various carcinomas and establishment of normal reference range
Cell-free DNA: measurement in various carcinomas and establishment of normal reference range
复制标题
DOI：
10.1016/s0009-8981(02)00091-8
复制
发表时间：
2002-07-01
影响因子：
5
通讯作者：
Wu, JT
中科院分区：
文献类型：
--
作者：
Wu, TL;Zhang, D;Wu, JT
背景：在循环血液中可检测到游离DNA。大量的文献报道指出，血浆或血清中的游离DNA有可能成为一种更特异的肿瘤诊断和预后的临床标志物。以及癌症的早期发现。研究方法：为了使无细胞DNA适用于常规临床实验室检测，我们使用了商业试剂盒，如用于DNA提取的Q1 Aamp血液试剂盒和用于DNA定量的PicoGreen DNA试剂盒。这样做是为了使我们的结果和建立的正常参考值能够与其他实验室进行比较。我们已经确定了20-70岁女性和男性无细胞DNA的正常参考水平。我们还在本研究中测试的所有癌症中检测到升高的细胞游离DNA，包括癌，白血病和淋巴瘤。结果如下：我们的研究表明，血清游离DNA的升高通常在含有升高的肿瘤标志物的标本中检测到，并且最有可能与肿瘤转移有关。游离DNA电泳图谱显示，肿瘤患者游离DNA呈碎片状，含有正常游离DNA中所没有的较小DNA（100 bp）。结论：游离DNA的检测可作为肿瘤标志物的补充，用于肿瘤患者的临床诊断。(C)2002 Elsevier Science B. V.保留所有权利。
Background: Cell-free DNA is detectable in circulating blood. Numerous reports in the literature have pointed out that cell-free DNA in plasma or serum has the clinical potential to be a more specific tumor marker for the diagnosis and prognosis. as well as the early detection, of cancer. Methods: In order to adapt cell-free DNA to a routine clinical laboratory test, we used commercial kits such as the Q1Aamp blood kit for DNA extraction and the PicoGreen DNA kit for DNA quantification. This was done so our results and the normal reference value established would allow to be compared by other laboratories. We have established the normal reference level of cell-free DNA for females and males from age 20-70 years. We also detected elevated cell-free DNA in all cancers that were tested in this study, including carcinomas, leukemia and lymphoma. Results: Our study indicates that the elevation of serum cell-free DNA was usually detected in specimens containing elevated tumor markers and is most likely associated with tumor metastases. The electrophoretic pattern of cell-free DNA showed that cell-free DNA from cancer patient is fragmented, containing smaller DNA (100 bp) not found in normal cell-free DNA, Conclusions: Measuring cell-free DNA may complement currently used tumor markers for the management of cancer patients. (C) 2002 Elsevier Science B.V. All rights reserved.